Product category:
Proteomics
News Release from: Bruker Daltonics | Subject: ClinProTools
Edited by the Laboratorytalk Editorial
Team on 03 August 2006
'Significant advance' in biomarker
discovery
New capability assists researchers and pharmaceutical firms in biomarker discovery and validation, discovering drug targets, and personalised medicine
Health Discovery has executed a non-exclusive worldwide license agreement with Bruker Daltonics covering Bruker Daltonics's use of HDC's Support Vector Machine (SVM) technology in the ClinProTools clinical proteomics product line ClinProTools is Bruker Daltonics's state-of-the-art bioinformatics solution for biomarker panel analysis, biofluid profiling, multivariate data analysis of large sample cohorts, classical statistics and sample classification
This article was originally published on Laboratorytalk on 2 Jun 2006 at 8.00am (UK)
Related stories
Integrated statistical image analysis of tissues
Integrated software packages allow researchers to merge statistical analysis on Maldi-Tof profiling spectra with molecular images of tissue distributions of peptide and protein biomarkers
Revolutionary ultra-high resolution TOF mass spec
At ASMS 2008, Bruker Daltonics announced the Maxis, a revolutionary new electrospray ultra-high resolution tandem TOF (UHR-Qq-TOF) mass spectrometer
Revolutionary mass spectrometer at ASMS conference
Bruker Daltonics will host a Users Symposium on Sunday 1 June to introduce Maxis, a novel high-speed, ultra high resolution time-of-flight (UHR-tof) mass spectrometer to the marketplace
The agreement provides for an up-front fee and royalties based on sales.
Herbert Fritsche, professor of laboratory medicine at the University of Texas's MD Anderson Cancer Center and chairman of HDC's Science Board, commented: "The combination of HDC's SVM pattern recognition technology with Bruker Daltonics's top-performing mass spectrometry systems - in particular its ClinProt product line - provides a significant advance in the field of biomarker discovery.
"This new capability will greatly assist diagnostic researchers and pharmaceutical companies in their efforts to discover new drug targets, early diagnostic tests, and companion diagnostics for monitoring drug therapy for personalized medicine".
"HDC is very excited about this new partnership with Bruker Daltonics," said Stephen Barnhill, HDC's chairman and chief executive officer.
"Bruker Daltonics is recognized as a leading innovator and developer of systems for clinical research based on mass spectrometry.
"Bruker's recognition of HDC's powerful SVM technology enhances its ability to meet the needs of its diverse customer base that includes the world's leading pharmaceutical and biotechnology companies".
Michael Schubert, executive vice president of Bruker Daltonics, stated: "We are pleased to enter into this agreement with HDC, the leader in SVM technology in bioinformatics applications.
"SVMs are high-performance supervised classification algorithms that can analyze high-dimensional mass spectrometric data from a plurality of sample cohorts.
"In essence, SVMs allow the mass spectrometer to become a more powerful system, thus complementing the use of other classification algorithms such as our Supervised Neural Network, our QuickClassifier, modified genetic algorithms, and others". Request a free brochure from Bruker Daltonics ...
• Bruker Daltonics: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
